ArticleIntegrative medicine research2026
Safety of herbal medicine in the postpartum period: A hospital-based single-arm, prospective observational study (SAFEHERE-PC).
Article in Integrative medicine research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Herbal medicines (HMs) are commonly used during the postpartum period in South Korea; however, comprehensive data regarding their safety remain limited. This study aimed to evaluate the safety of HM use among postpartum women through the "SAFEty of HErbal medicine REgistry in Postpartum Care center" (SAFEHERE-PC) study. Methods: A single-arm, prospective observational study was conducted from March to December 2024, enrolling 186 women within six weeks postpartum who were admitted to the postpartum care center of a Korean Medicine hospital. The study monitored adverse events (AEs) during HM use, collecting demographic information, medical history, herbal prescription details, and AE data. Reported AEs were analyzed using the WHO-UMC causality assessment and the Naranjo algorithm. Results: Of the 186 participants, 4 (2.2 %) experienced AEs following HM administration, all of which were gastrointestinal symptoms (diarrhea, loose stools). Three of the five events were managed with a short course of the herbal formula, and two cases resolved spontaneously without requiring medical intervention. Based on severity and clinical course, the events were classified as mild to moderate. Causality assessment using the WHO-UMC system classified four cases as "possible" and one as "certain", while the Naranjo scale indicated three cases as "possible" and two as "probable" in their association with HM use. Conclusion: A low incidence of mild gastrointestinal AEs (2.2 % of patients; 0.6 % of prescriptions) was observed, with no serious AEs reported. These findings provide descriptive safety data specific to the formulations and clinical practices used at this hospital-based postpartum care center. Trial registration: Korean National Clinical Trial Registry Clinical Research Information Service: KCT0009060.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.